Suppr超能文献

健康受试者单次及多次静脉输注氧氟沙星后的药代动力学。 (注:原英文表述“Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.”中多了一个“of”,正确表述应为“Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects” )

Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.

作者信息

Farinotti R, Trouvin J H, Bocquet V, Vermerie N, Carbon C

机构信息

Department of Pharmacy, Hôpital Bichat, Paris, France.

出版信息

Antimicrob Agents Chemother. 1988 Oct;32(10):1590-2. doi: 10.1128/AAC.32.10.1590.

Abstract

The pharmacokinetics of ofloxacin were investigated in eight healthy male volunteers. A single infusion (200 mg over 0.5 h) was performed on day 1, followed by a washout period of 2 weeks. Repeated administrations were performed for 4 days (200 mg every 12 h). Pharmacokinetic parameters were determined from the plasma decay curves of the single and the last of the multiple administrations. Ofloxacin kinetics after the single dose were best described by a two-phase curve with a total body clearance of 241.6 +/- 43.3 ml min-1, a volume of distribution of 112 +/- 23.1 liters, and an elimination half-life of 5.4 +/- 0.8 h. The extrapolated area under the curve (AUC0-infinity) was 14 +/- 2.3 mg.h liter-1. The pharmacokinetics were not significantly modified by repeated administration, demonstrated mainly by the AUC0-12 value of the last infusion (13.4 +/- 2.2 mg.h liter-1). We conclude that, with intravenous multiple doses every 12 h, the steady state is reached within 24 to 36 h and no abnormal accumulation or changes in pharmacokinetic parameters occur.

摘要

在8名健康男性志愿者中研究了氧氟沙星的药代动力学。第1天进行单次输注(0.5小时内输注200毫克),随后有2周的洗脱期。重复给药4天(每12小时200毫克)。根据单次给药和多次给药最后一次给药后的血浆衰减曲线确定药代动力学参数。单次给药后氧氟沙星的动力学最好用双相曲线描述,全身清除率为241.6±43.3毫升·分钟-1,分布容积为112±23.1升,消除半衰期为5.4±0.8小时。曲线下面积外推值(AUC0-∞)为14±2.3毫克·小时·升-1。多次给药未显著改变药代动力学,主要由最后一次输注的AUC0-12值(13.4±2.2毫克·小时·升-1)证明。我们得出结论,每12小时静脉注射多次剂量,在24至36小时内达到稳态,药代动力学参数无异常蓄积或变化。

相似文献

1
Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.
Antimicrob Agents Chemother. 1988 Oct;32(10):1590-2. doi: 10.1128/AAC.32.10.1590.
4
Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers.
Antimicrob Agents Chemother. 1992 Feb;36(2):308-12. doi: 10.1128/AAC.36.2.308.
5
Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.
Antimicrob Agents Chemother. 1996 Sep;40(9):2167-72. doi: 10.1128/AAC.40.9.2167.
6
Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin.
J Antimicrob Chemother. 1988 Sep;22 Suppl C:73-9. doi: 10.1093/jac/22.supplement_c.73.
8
Pharmacokinetics of ofloxacin in broiler chicken.
J Vet Pharmacol Ther. 2006 Jun;29(3):185-9. doi: 10.1111/j.1365-2885.2006.00729.x.
9
Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.
Antimicrob Agents Chemother. 1992 Mar;36(3):552-7. doi: 10.1128/AAC.36.3.552.
10
Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
Antimicrob Agents Chemother. 1994 Apr;38(4):799-804. doi: 10.1128/AAC.38.4.799.

引用本文的文献

1
Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01122-17. Print 2017 Oct.
2
Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.
Antimicrob Agents Chemother. 1996 Sep;40(9):2167-72. doi: 10.1128/AAC.40.9.2167.
3
Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis.
Antimicrob Agents Chemother. 1996 Jul;40(7):1589-93. doi: 10.1128/AAC.40.7.1589.
5
Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.
Antimicrob Agents Chemother. 1991 Feb;35(2):384-6. doi: 10.1128/AAC.35.2.384.
6
Ofloxacin pharmacokinetics in mechanically ventilated patients.
Antimicrob Agents Chemother. 1991 Aug;35(8):1582-5. doi: 10.1128/AAC.35.8.1582.
8
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.
Drugs. 1991 Nov;42(5):825-76. doi: 10.2165/00003495-199142050-00008.
9
Ofloxacin clinical pharmacokinetics.
Clin Pharmacokinet. 1992 Jan;22(1):32-46. doi: 10.2165/00003088-199222010-00004.

本文引用的文献

1
Pharmacokinetics of ofloxacin after parenteral and oral administration.
Antimicrob Agents Chemother. 1987 Sep;31(9):1338-42. doi: 10.1128/AAC.31.9.1338.
2
Ofloxacin pharmacokinetics in renal failure.
Antimicrob Agents Chemother. 1987 Feb;31(2):156-60. doi: 10.1128/AAC.31.2.156.
4
Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.
J Antimicrob Chemother. 1986 Jun;17(6):795-800. doi: 10.1093/jac/17.6.795.
5
The effect of food on the pharmacokinetics of ofloxacin.
Curr Med Res Opin. 1986;10(3):166-71. doi: 10.1185/03007998609110436.
6
Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1987 Apr;33(4):346-91. doi: 10.2165/00003495-198733040-00003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验